Author | Lightnews

Reposted by John Kim

Kerri Johannson MD MPH @kerrijohannson.bsky.social · 2d

Okay #MedSky #AcademicSky 📚

What is the optimal number of reviewers for a run-of-the-mill manuscript @ reg journal (i.e. not Science/NEJM)

Some journals invite 4-5 as default 🤯
I think 2 is sufficient, max 3 if controversy

More reviewers ➡️ less AE provides input
And SO many hours of free labour 💪

a man says " it 's too much " in front of a window

Alt: Schitt’s creek David says " it 's too much " in front of a window

media.tenor.com

2 3 9

John Kim @jskim8223.bsky.social · 28d

Thrilled our paper made it to the @atsblueeditor.bsky.social ILD issue this month. Look forward to building on this work and welcome collaboration with anyone interested in subclinical pulmonary fibrosis. I think a future research area is mapping the blood-lung proteome in this context.

ATS Blue Journal @atsblueeditor.bsky.social · 28d

Associations of High Attenuation Area–Related Proteomic Biomarkers with Fibrotic or Subpleural Interstitial Lung Abnormalities
@jskim8223.bsky.social @atscommunity.bsky.social #medsky

🔗 tinyurl.com/da3jsx8n

Reposted by John Kim

ATS Blue Journal @atsblueeditor.bsky.social · Oct 3

The Blue Journal thanks Riley Hannan, PhD, for his contribution to the October issue

Associations of High Attenuation Area-Related Proteomic Biomarkers with Fibrotic or Subpleural Interstitial Lung Abnormalities
@jskim8223.bsky.social

www.atsjournals.org/doi/full/10....

1 1

John Kim @jskim8223.bsky.social · Sep 2

a man is laying on a couch wearing a blue shirt and making a funny face .

ALT: a man is laying on a couch wearing a blue shirt and making a funny face .

media.tenor.com

1 1

John Kim @jskim8223.bsky.social · Sep 2

Time to update the guidelines. Pretty exciting stuff.

1 1

John Kim @jskim8223.bsky.social · Aug 25

Our paper is online @atsblueeditor.bsky.social identifying plasma protein markers with HAA and correlating to new-onset fibrotic/subpleural ILA. Big thanks to our collaborators in #MESA & #SPIROMICS!
www.atsjournals.org/doi/abs/10.1...

Associations of High Attenuation Area-related Proteomic Biomarkers with Fibrotic or Subpleural Interstitial Lung Abnormalities | American Journal of Respiratory and Critical Care Medicine | Articles i...

www.atsjournals.org

2

Reposted by John Kim

ATS Blue Journal @atsblueeditor.bsky.social · Jul 23

Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement
@atscommunity.bsky.social #medsky

🔓 Open Access

🔗 tinyurl.com/4vjm9zdw

4 5

John Kim @jskim8223.bsky.social · Apr 30

Current work playlist while writing. Any other music #PCCM are putting on in the background for work? @kaminskimed.bsky.social @kerrijohannson.bsky.social @ipfdoc.bsky.social @drdayjee.bsky.social @emilyfri.bsky.social @drpujamehta1.bsky.social?
open.spotify.com/playlist/37i...

Sinners Official Playlist

Playlist · Spotify · 74 items · 50.9K saves

open.spotify.com

4 1 5

Reposted by John Kim

The Lancet Respiratory Medicine @lancetrespirmed.bsky.social · Apr 29

🧬 Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation

📈 Non-additive effects were seen between qualifying variants and common risk variants in #IPF survival

🔗 www.thelancet.com/journals/lan...

Image of DNA double helix and fingerprint representing genetic fingerprint
Copyright © 2025 KTSDesign/Science Photo Library

1 1 2

Reposted by John Kim

Aitana Alonso @aitanaag90.bsky.social · Apr 29

Delighted to share our new study evaluating the association of rare variants in telomere and non-telomere monogenic adult-onset Pulmonary Fibrosis genes and IPF patient survival where we also intersected their effects with #PRS of IPF.

The Lancet Respiratory Medicine @lancetrespirmed.bsky.social · Apr 29

🧬 Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation

📈 Non-additive effects were seen between qualifying variants and common risk variants in #IPF survival

🔗 www.thelancet.com/journals/lan...

1 4 4

John Kim @jskim8223.bsky.social · Apr 12

Had the privilege giving a talk about early ILD detection and sharing some of the research we are doing at #KATRD annual meeting in #Gyeongju. Thank you for the opportunity and meeting so many wonderful pulmonologists.

2

John Kim @jskim8223.bsky.social · Apr 2

🤯🤯🤯

1

John Kim @jskim8223.bsky.social · Mar 22

Informative piece in @naturerevdrugdisc.bsky.social on cross-organ fibrosis and informing drug development. @ipfdoc.bsky.social @gilliangoobie.bsky.social @kerrijohannson.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @drdayjee.bsky.social
www.nature.com/articles/s41...

Fibrosis: cross-organ biology and pathways to development of innovative drugs - Nature Reviews Drug Discovery

Fibrosis is a key characteristic of a range of chronic diseases that has been challenging to target with drugs. This Review highlights core pathways active in fibrotic conditions across organs, as wel...

www.nature.com

4 13

Reposted by John Kim

Nick Banovich @nebanovich.bsky.social · Feb 4

Excited to post my first #skySplain about our recent work published yesterday in Nature Genetics! www.nature.com/articles/s41.... One of the first authors of this study - Annika Vannan – actually wrote this breakdown, but she's not yet over here on bluesky and asked me to post!

Spatial transcriptomics identifies molecular niche dysregulation associated with distal lung remodeling in pulmonary fibrosis - Nature Genetics

Xenium spatial transcriptomic profiling of pulmonary fibrosis characterizes cell composition dynamics and histopathological features associated with the disease.

www.nature.com

3 23 55

Reposted by John Kim

Annals of the ATS @annalsats.bsky.social · Jan 14

Genomic and Serological Rheumatoid Arthritis Biomarkers, MUC5B Promoter Variant, and Interstitial Lung Abnormalities
@atscommunity.bsky.social #medsky

🔗 tinyurl.com/mr4cke25

2 6

Reposted by John Kim

Kerri Johannson MD MPH @kerrijohannson.bsky.social · Jan 4

🌟 Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease 🌟

Just out in @atsblueeditor.bsky.social 🫁

www.atsjournals.org/doi/abs/10.1...

State of the Art:
-Epidemiology
-Mechanisms of Injury
-Implications - clinical & policy
-Future directions

Screenshot of the article title and authors

1 6 21

John Kim @jskim8223.bsky.social · Dec 27

Count me in, thanks for organizing!

1 1 2

Reposted by John Kim

Kerri Johannson MD MPH @kerrijohannson.bsky.social · Dec 21

Now can we use CA-125 as a theragnostic biomarker of treatment response in patients with IPF? Why wouldn't we?

@ipfdoc.bsky.social @kaminskimed.bsky.social
#CurePF #CureIPF @ats-clinicalprobs.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social

pmc.ncbi.nlm.nih.gov/articles/pmi...

screenshot of study title. Effects of nintedanib on biomarkers in IPF in ERJ Open.

2 6 10

Reposted by John Kim

ATS Blue Journal @atsblueeditor.bsky.social · Dec 18

The Blue Journal thanks Catherine L. Debban, PhD, for her contribution to the December 15 issue

Dysanapsis Genetic Risk Predicts Lung Function Across the Lifespan

www.atsjournals.org/doi/full/10....

1 2

Reposted by John Kim

Christopher Nemeh, MD @cnemehmd.bsky.social · Dec 15

Question for intensivists regarding theoretical vs observed risk tolerance. How much consideration or pause (if any) are you given when starting inhaled pulmonary vasodilators for refractory hypoxemia if the patient has concurrent left heart dysfunction?

#MedSky #EMIMCC #CritCareSky #CardioSky

7 4 6

Reposted by John Kim

Jack Iwashyna @iwashyna.bsky.social · Dec 6

last night, Hallie Prescott had her NEJM review on sepsis released: www.nejm.org/doi/full/10....

Today I had the pleasure of giving some remarks on her installation as the Toews Family Legacy Professor at the University of Michigan

Sepsis and Septic Shock | NEJM

Sepsis is a life-threatening, heterogeneous disorder involving a dysregulated immune response to infection. Research to identify subtypes and targeted therapies for host dysregulation is ongoing.

www.nejm.org

3 14 62

Reposted by John Kim

Gísli @ipfdoc.bsky.social · Dec 5

Using Mendelian Randomisation to identify causal associations in #IPF a 🧵

1 2 8

John Kim @jskim8223.bsky.social · Dec 3

Current ATS member here, thanks!

1

Reposted by John Kim

Kerri Johannson MD MPH @kerrijohannson.bsky.social · Nov 14

For the new BlueSky members who have left #ILDTwitter I’ve updated this starter-pack to help you find key ILD and ILD-adjacent community members here. Pls comment if I’ve missed you and I’ll add you 🫁😊
#CurePF #CureIPF #ILD

go.bsky.app/8u4KcNo

5 8 13